X4 Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

De CEO X4 Pharmaceuticals is Paula Ragan, benoemd in Jul2014, heeft een ambtstermijn van 10.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.04M, bestaande uit 30.3% salaris en 69.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.61% van de aandelen van het bedrijf, ter waarde € 469.92K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.5 jaar en 5.6 jaar.

Belangrijke informatie

Paula Ragan

Algemeen directeur

US$2.0m

Totale compensatie

Percentage CEO-salaris	30.3%
Dienstverband CEO	10.3yrs
Eigendom CEO	0.6%
Management gemiddelde ambtstermijn	3.5yrs
Gemiddelde ambtstermijn bestuur	5.6yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Paula Ragan's beloning veranderd ten opzichte van X4 Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	US$18m
Mar 31 2024	n/a	n/a	-US$129m
Dec 31 2023	US$2m	US$620k	-US$101m
Sep 30 2023	n/a	n/a	-US$111m
Jun 30 2023	n/a	n/a	-US$131m
Mar 31 2023	n/a	n/a	-US$96m
Dec 31 2022	US$4m	US$583k	-US$96m
Sep 30 2022	n/a	n/a	-US$103m
Jun 30 2022	n/a	n/a	-US$102m
Mar 31 2022	n/a	n/a	-US$100m
Dec 31 2021	US$2m	US$562k	-US$103m
Sep 30 2021	n/a	n/a	-US$85m
Jun 30 2021	n/a	n/a	-US$82m
Mar 31 2021	n/a	n/a	-US$78m
Dec 31 2020	US$3m	US$543k	-US$62m
Sep 30 2020	n/a	n/a	-US$55m
Jun 30 2020	n/a	n/a	-US$55m
Mar 31 2020	n/a	n/a	-US$53m
Dec 31 2019	US$2m	US$492k	-US$53m
Sep 30 2019	n/a	n/a	-US$55m
Jun 30 2019	n/a	n/a	-US$46m
Mar 31 2019	n/a	n/a	-US$40m
Dec 31 2018	US$921k	US$380k	-US$36m

Compensatie versus markt: De totale vergoeding ($USD 2.04M ) Paula } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 492.53K ).

Compensatie versus inkomsten: De vergoeding van Paula is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Paula Ragan (54 yo)

10.3yrs

Tenure

US$2,044,761

Compensatie

Dr. Paula Ragan, Ph D., is Member of Advisory Board of Tippingpoint Biosciences, Inc. Dr. Ragan serves as an Independent Director of CAMP4 Therapeutics Corporation since May 2019. She is a Founder of X4 Ph...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Paula Ragan	CEO, President & Director	10.3yrs	US$2.04m	0.61% € 469.9k
Adam Mostafa	CFO, Treasurer & Corporate Secretary	6.1yrs	US$1.15m	geen gegevens
Christophe Arbet-Engels	Chief Medical Officer	1.2yrs	US$1.64m	geen gegevens
Richard Peters	Founder	no data	geen gegevens	geen gegevens
Renato Skerlj	Founder	no data	geen gegevens	geen gegevens
Keith Flaherty	Founder & Member of Corporate Advisory Board	no data	geen gegevens	geen gegevens
Mary DiBiase	Chief Operating Officer	3.1yrs	US$1.84m	0.27% € 207.1k
Arthur Taveras	Chief Scientific Officer	3.9yrs	geen gegevens	0.23% € 177.8k
Robert Arbeit	Senior Vice President of Clinical Development and Translational Research	no data	geen gegevens	geen gegevens
Mark Baldry	Chief Commercial Officer	1.9yrs	geen gegevens	0.029% € 22.2k

3.5yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 48Q wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Paula Ragan	CEO, President & Director	10.3yrs	US$2.04m	0.61% € 469.9k
Keith Flaherty	Founder & Member of Corporate Advisory Board	8.5yrs	geen gegevens	geen gegevens
Michael Wyzga	Independent Chairman of the Board	6.3yrs	US$199.34k	0.045% € 35.1k
Gary Bridger	Director	5.6yrs	US$147.05k	0.031% € 23.7k
David W. McGirr	Independent Director	7.1yrs	US$166.05k	0.031% € 23.7k
Alison Lawton	Independent Director	4yrs	US$154.55k	0.031% € 23.7k
William Aliski	Independent Director	5.1yrs	US$165.05k	0.031% € 23.7k
Michael Vasconcelles	Member of Corporate Advisory Board	8.5yrs	geen gegevens	geen gegevens
Robert Woods	Independent Director	less than a year	US$91.83k	geen gegevens
Murray Stewart	Director	5.6yrs	US$90.08k	0.087% € 67.1k
Francoise de Craecker	Independent Director	3yrs	US$152.05k	0.031% € 23.7k

5.6yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 48Q wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.6 jaar).

X4 Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

X4 Pharmaceuticals Announces Appoints Veteran R. Keith Woods to Board of Directors

Director recently sold €125k worth of stock

X4 Pharmaceuticals, Inc. Announces Appointment of Dr. Christophe Arbet-Engels to Join as Chief Medical Officer

X4 Pharmaceuticals, Inc. Announces Executive Changes

X4 Pharmaceuticals Announces Appointment of Industry Veteran Mark Baldry as Chief Commercial Officer

X4 Pharmaceuticals, Inc. Announces the Resignation of Derek Meisner from His Position as Chief Legal Officer and Corporate Secretary of the Company, Effective August 22, 2022

Recent updates

X4 Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 13, 2024

New minor risk - Market cap size

X4 Pharmaceuticals Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(a)(2)

X4 Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024

X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) dropped from Russell Small Cap Comp Value Index

X4 Pharmaceuticals, Inc. Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (Cn) and Initiation of Pivotal Phase 3 Cn Trial

New major risk - Financial position

X4 Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

X4 Pharmaceuticals, Inc. Announces FDA Approval of XOLREMDI (mavorixafor) Capsules, First Drug Indicated in Patients with Whim Syndrome

X4 Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 21, 2024

X4 Pharmaceuticals, Inc. Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023

X4 Pharmaceuticals, Inc. Receives A Deficiency Letter from Nasdaq Regarding Bid Price Rule

X4 Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in Whim Syndrome

X4 Pharmaceuticals Announces Appoints Veteran R. Keith Woods to Board of Directors

X4 Pharmaceuticals Announces Submission of New Drug Application (Nda) to U.S. Fda for Mavorixafor in Whim Syndrome

Now 23% undervalued after recent price drop

Director recently sold €125k worth of stock

X4 Pharmaceuticals, Inc. Announces Appointment of Dr. Christophe Arbet-Engels to Join as Chief Medical Officer

X4 Pharmaceuticals, Inc. announced that it expects to receive $115 million in funding

X4 Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 10, 2023

X4 Pharmaceuticals, Inc. Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Time of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome

X4 Pharmaceuticals’ Presentations at ASH 2022 Further Highlight Opportunity for Mavorixafor in the Treatment of Chronic Neutropenia

X4 Pharmaceuticals, Inc. has completed a Follow-on Equity Offering.

X4 Pharmaceuticals Announces Positive Top-Line Results from 4Whim Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in Whim Syndrome

X4 Pharmaceuticals, Inc. Announces Executive Changes

X4 Pharmaceuticals Announces Appointment of Industry Veteran Mark Baldry as Chief Commercial Officer

X4 Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022

X4 Pharmaceuticals Announces New Positive Phase 1b Data Supporting Mavorixafor’s Broad Potential in Chronic Neutropenia (CN)

X4 Pharmaceuticals, Inc. Announces the Resignation of Derek Meisner from His Position as Chief Legal Officer and Corporate Secretary of the Company, Effective August 22, 2022

X4 Pharmaceuticals, Inc. Announces Strategic Prioritization of Programs and Resources Extending Cash Runway Through Expected Key Clinical and Regulatory Milestones

X4 Pharmaceuticals, Inc. announced that it expects to receive $55.763275 million in funding from New Enterprise Associates, Inc., Acorn Bioventures, Lumira Ventures, Bain Capital Life Sciences Investors, LLC, OrbiMed Advisors LLC, Hercules Capital, Inc.

X4 Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 12, 2022

X4 Pharmaceuticals, Inc. Presents New Clinical and Scientific Data At 2021 ASH Annual Meeting Supporting Broader Potential for Mavorixafor in the Treatment of Primary Immunodeficiencies

X4 Pharmaceuticals, Inc. Presents New Clinical Data at ASH 2021 Further Supporting Potential of Mavorixafor + Ibrutinib to Treat Patients with Double-Mutation Waldenström’s Macroglobulinemia

X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) dropped from Russell Microcap Value Index

X4 Pharmaceuticals Announces Presentation of Positive Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia at EHA 2021

X4 Pharmaceuticals Announces Positive Preliminary Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia as Published in EHA Abstract

X4 Pharmaceuticals, Inc. Provides an Update on its Lead Product Candidate, Mavorixafor, a Novel Small Molecule Currently Being Evaluated in a Phase 3 Clinical Trial

New 90-day high: €8.30

Revenue beats expectations

X4 Pharmaceuticals, Inc. Provides an Update on Its Lead Product Candidate, Mavorixafor

X4 Pharmaceuticals, Inc. to Report Q4, 2020 Results on Mar 04, 2021

New 90-day high: €7.30

New 90-day high: €6.15

X4 Pharmaceuticals, Inc. Appoints Diego Cadavid, M.D., as Chief Medical Officer

X4 Pharmaceuticals, Inc. Receives Rare Pediatric Disease Designation from FDA for Mavorixafor for the Treatment of Whim Syndrome

X4 Pharmaceuticals, Inc. Announces the Appointment of Art Taveras as Chief Scientific Officer

New 90-day low: €5.00

X4 Pharmaceuticals, Inc. has Re-Assessed the Impacts of the Continuing COVID-19 Pandemic on the Ongoing Phase 1B Dose-Escalation Trial

X4 Pharmaceuticals, Inc. Announces Board Changes, Effective October 5, 2020

New 90-day low - €5.95

New 90-day low - €6.25

X4 Pharmaceuticals, Inc. to Report Q2, 2020 Results on Jul 30, 2020

X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) dropped from Russell 3000 Growth Index

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd